DEVELOPMENT AND OPTION AGREEMENT betweenDevelopment and Option Agreement • March 12th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Development and Option Agreement (the “Agreement”) is made and entered into effective as of November 20, 2019 (the “Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd, a Bermuda corporation (“AbbVie”). Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SECOND AMENDED AND RESTATED ASSIGNMENT AND LICENSE AGREEMENTAssignment and License Agreement • March 12th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Second Amended and Restated Assignment and License Agreement (this “Agreement”) is entered into as of December 20, 2019 (the “Second Amendment Date”), by and between Werewolf Therapeutics, Inc., a Delaware corporation, with a place of business at 1030 Massachusetts Avenue, 2nd Floor, Cambridge, MA 02138 (“Werewolf”), and Harpoon Therapeutics, Inc., a Delaware corporation with a place of business at 4000 Shoreline Court, Suite 250, South San Francisco, CA 94080 (“Harpoon”).
HARPOON THERAPEUTICS, INC. FIFTH AMENDED AND RESTATED CONSULTING AGREEMENTConsulting Agreement • March 12th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS FIFTH AMENDED AND RESTATED CONSULTING AGREEMENT (this “Agreement”) dated as of March 3, 2020 is entered into between Harpoon Therapeutics, Inc., a Delaware corporation (the “Company”), and Patrick Baeuerle (the “Consultant”) and amends and restates the Third Amended and Restated Consulting Agreement dated February 1, 2017 between the Company and the Consultant, as amended by the Fourth Amended and Restated Consulting Agreement dated March 5, 2018 between the Company and the Consultant.
AMENDED AND RESTATED DISCOVERY COLLABORATION AND LICENSE AGREEMENT betweenDiscovery Collaboration and License Agreement • March 12th, 2020 • Harpoon Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Discovery Collaboration and License Agreement (the “Agreement”) is made and entered into effective as of 20 November, 2019 (the “Amended Effective Date”) by and between Harpoon Therapeutics, Inc., a Delaware corporation (“Harpoon”), and AbbVie Biotechnology Ltd., a Bermuda corporation (“AbbVie”). Harpoon and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
